local_hospital

University Of Pecs

Address
lock Available on a paid plan

Skin and Connective Tissue Diseases and Oncodermatology

At the University Of Pecs Department of Dermatology, Venerology and Oncodermatology, clinical research in skin and connective tissue diseases focuses on inflammatory and autoimmune conditions, along with difficult-to-treat skin disorders and skin cancers. The studies are designed to test new therapies, assess symptom control, and support longer-term treatment safety.

  • Alopecia areata research exploring whether a new treatment can improve hair regrowth in children
  • Atopic dermatitis and hidradenitis suppurativa trials evaluating symptom relief and treatment effectiveness
  • Psoriasis studies comparing emerging options for moderate to severe disease, including special-area involvement
  • Lupus erythematosus research focused on improving disease control and long-term safety of therapy
  • Cutaneous squamous cell carcinoma and melanoma trials assessing new approaches for advanced skin cancer

Overall, this research area combines autoimmune dermatology with oncodermatology, reflecting a strong interest in both chronic inflammatory skin disease and cancer care.

Immune System Diseases and Immune System Processes

Clinical trials at this site also cover a broad range of immune system diseases, with an emphasis on conditions driven by abnormal immune activity. The research aims to better understand disease mechanisms while evaluating therapies that may reduce flares, improve symptoms, and offer more durable control.

  • Systemic lupus erythematosus studies testing new options for active disease
  • IgG4-related disease research examining ways to prevent relapse after initial treatment
  • Systemic sclerosis trials looking at improvement in signs, symptoms, and disease impact
  • Dermatomyositis studies evaluating whether novel treatment can reduce disease activity
  • Autoimmune disease research supporting broader understanding of immune-driven inflammation

These studies reflect a strong focus on immunology and on finding more effective, better-tolerated treatments for complex systemic conditions.

Musculoskeletal Diseases and Systemic Inflammatory Disorders

Research in musculoskeletal diseases at the site includes inflammatory conditions that affect joints, muscles, and connective tissues. The clinical trials are centered on improving disease control, easing pain and stiffness, and helping patients maintain daily function.

  • Axial spondyloarthritis studies assessing whether a new therapy can improve signs and symptoms
  • Dermatomyositis trials focused on reducing inflammation and improving muscle-related outcomes
  • Systemic sclerosis research examining broader effects on mobility and disease burden
  • Immune-mediated connective tissue disease studies aimed at better symptom management

This work highlights the site’s interest in rheumatology-related research and in therapies that may improve long-term quality of life for people with chronic inflammatory disease.

Eye Diseases

At University Of Pecs, the eye diseases portfolio includes research into retinal conditions that can affect vision and daily functioning. The main goal is to evaluate new treatment approaches that may improve ocular outcomes and expand options beyond standard care.

  • Diabetic macular edema studies assessing safety, tolerability, and visual benefit of a new treatment approach
  • Retinal disease research aimed at improving control of fluid-related eye damage

These trials reflect a practical focus on ophthalmology, especially conditions where better treatment options could help preserve sight.

Site Overview

assignment
18
connected trials
corporate_fare
15
sponsors
science
24
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
18
Total trials linked
Highly Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 6 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
2
Sponsors (total)
15
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
18
Outperforms 79% of sites
public
Therapeutic diversity
6areas
Outperforms 86% of sites
groups
Sponsor diversity
15sponsors
Outperforms 86% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in University Of Pecs

lock Showing 1 of 18 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaIncyte Corp.Phase IINot Yet RecruitingOct 2023Mar 2026

IMP list

lock Showing 1 of 24 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Upadacitinib3Unknown2019-01-092023-11-20

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.